Although the full implications of the discovery are not yet concrete, this is a very exciting breakthrough.

There was overreaction, but at the same hand there probably was an overreaction to the genomics companies over the past few months. These are very highly volatile stocks ... they are very, very sensitive to the stock market itself, and also to news.

The further you are from a commercial product, the riskier it is.

This is very disappointing. This is the last stage of development of the drug. We're really playing for keeps at this level.

Do not think this is the end of it. This is a very, very exciting time in terms of biotech.

For the artist, drawing is discovery. And that is not just a slick phrase; it is quite literally true.